Despite widespread statin therapy, 91% of cardiac transplant patients have hyperlipidemia within 5 years from cardiac transplantation. The implications of this are profound, particularly given that coronary allograft vasculopathy is a leading cause of death. Unfortunately the solution is not easy, with problems of toleration at higher statin doses and a lack of good quality evidence for second line agents. We review the literature and discuss some of the key issues transplant physicians are faced with when considering alternatives to statin therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1755-5922.2012.00315.x | DOI Listing |
Publication Analysis
Top Keywords
cardiac transplantation
8
statin therapy
8
second options
4
options hyperlipidemia
4
hyperlipidemia management
4
management cardiac
4
transplantation despite
4
despite widespread
4
widespread statin
4
therapy 91%
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!